DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,088 filers reported holding DANAHER CORPORATION in Q2 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,000,713,000 | +21.3% | 3,728,993 | +1.8% | 1.09% | +10.0% |
| Q1 2021 | $824,860,000 | +4.3% | 3,664,742 | +2.9% | 0.99% | -4.1% |
| Q4 2020 | $791,209,000 | +4.3% | 3,561,757 | +1.1% | 1.03% | -13.0% |
| Q3 2020 | $758,597,000 | +17.5% | 3,522,952 | -3.5% | 1.19% | +6.7% |
| Q2 2020 | $645,701,000 | +34.8% | 3,651,534 | +5.5% | 1.11% | +8.4% |
| Q1 2020 | $479,126,000 | +0.4% | 3,461,644 | +11.3% | 1.03% | +21.6% |
| Q4 2019 | $477,316,000 | -44.6% | 3,109,955 | -47.9% | 0.84% | -6.9% |
| Q3 2019 | $862,046,000 | +107.2% | 5,968,610 | +105.0% | 0.91% | +1.1% |
| Q2 2019 | $416,019,000 | +4.1% | 2,910,849 | -3.8% | 0.90% | +1.8% |
| Q1 2019 | $399,502,000 | +16.3% | 3,026,075 | -9.2% | 0.88% | +2.3% |
| Q4 2018 | $343,604,000 | +1.7% | 3,332,078 | +7.2% | 0.86% | +20.6% |
| Q3 2018 | $337,717,000 | +12.8% | 3,108,016 | +2.5% | 0.71% | -0.3% |
| Q2 2018 | $299,322,000 | +0.1% | 3,033,262 | -0.7% | 0.72% | -3.0% |
| Q1 2018 | $299,100,000 | +3.9% | 3,054,845 | -1.5% | 0.74% | -0.4% |
| Q4 2017 | $287,938,000 | +5.1% | 3,102,105 | -2.9% | 0.74% | -4.5% |
| Q3 2017 | $274,044,000 | +20.4% | 3,194,728 | +19.3% | 0.78% | +10.9% |
| Q2 2017 | $227,555,000 | +6.0% | 2,679,003 | +6.8% | 0.70% | 0.0% |
| Q1 2017 | $214,623,000 | +5.5% | 2,509,334 | -3.9% | 0.70% | -7.4% |
| Q4 2016 | $203,353,000 | +3.3% | 2,612,439 | +4.1% | 0.76% | +2.2% |
| Q3 2016 | $196,787,000 | -8.5% | 2,510,364 | +14.8% | 0.74% | -11.9% |
| Q2 2016 | $215,034,000 | +6.1% | 2,186,200 | -3.7% | 0.84% | -6.1% |
| Q1 2016 | $202,718,000 | -3.5% | 2,270,840 | +0.4% | 0.90% | +0.7% |
| Q4 2015 | $209,973,000 | +9.5% | 2,260,694 | +0.4% | 0.89% | +5.3% |
| Q3 2015 | $191,801,000 | -7.1% | 2,250,922 | -0.2% | 0.84% | 0.0% |
| Q2 2015 | $206,528,000 | +31.0% | 2,255,654 | +17.1% | 0.84% | +28.9% |
| Q1 2015 | $157,664,000 | -1.3% | 1,925,553 | +3.3% | 0.66% | -8.4% |
| Q4 2014 | $159,769,000 | +11.1% | 1,864,055 | -1.5% | 0.72% | +3.3% |
| Q3 2014 | $143,763,000 | -19.6% | 1,892,123 | -16.7% | 0.69% | -18.8% |
| Q2 2014 | $178,821,000 | -5.0% | 2,271,320 | -9.5% | 0.85% | -9.5% |
| Q1 2014 | $188,331,000 | -3.2% | 2,511,079 | -0.4% | 0.94% | -5.9% |
| Q4 2013 | $194,554,000 | +11.1% | 2,520,137 | -0.2% | 1.00% | +2.2% |
| Q3 2013 | $175,108,000 | +4.8% | 2,526,075 | -4.3% | 0.98% | +2.3% |
| Q2 2013 | $167,160,000 | – | 2,640,757 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |